The partnership provides access to Xencor’s Fc engineering patents for monoclonal antibodies.
Xencor, a biopharmaceutical company specializing in antibody engineering technology, has entered into a technology license and option agreement to provide Merck & Co. access to one of Xencor’s Fc engineering patents for a therapeutic monoclonal antibody.
Under the agreement, Merck will be granted a nonexclusive license to a Xencor patent for use in an undisclosed product as well as an option to license the same intellectual property for future products. Xencor will receive an upfront payment and annual maintenance fees. Xencor is also eligible to receive milestone payments associated with the successful development of Merck product candidates as well as royalties on sales of any potential products that may result from this agreement, according to a Xencor statement.
Xencor engineers biotherapeutics using its proprietary Protein Design Automation technology platform, which is used in antibody engineering to improve antibody half-life, immune-regulatory function, and potency. The company is advancing multiple proprietary XmAb antibody drug candidates in the clinic, including XmAb5871 targeting CD32b and CD19 for autoimmune diseases, and the anti-CD30 candidate XmAb2513 for the treatment of Hodgkin’s lymphoma. Xencor is also advancing a portfolio of biosuperior versions of blockbuster antibody drugs engineered for improved half-life and dosing schedules. Xencor has partnerships with Amgen, Pfizer, Janssen R&D, MorphoSys, Boehringer Ingelheim, CSL, and Human Genome Sciences (now part of GlaxoSmithKline). In these partnerships, Xencor is applying its proprietary antibody Fc domains to improve antibody drug candidates for traits such as sustained half-life and/or potency, according to company information.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.